Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Song, Chang ^a   Sadashivaiah, Kavitha ^a   Furusawa, Aki ^a   Davila, Eduardo ^a   Tamada, Koji ^b   Banerjee, Arnob ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

4 1BB; Eomesodermin; Lag3; PD 1; T cells; Tumor immunotherapy

Indexed keywords

4 1 BB ANTIBODY; CD137 ANTIGEN; CELL ANTIBODY; EOMESODERMIN; LYMPHOCYTE ACTIVATION GENE 3; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL FATE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC CORRELATION; LYMPHOMA; MOUSE; NONHUMAN; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84899101852     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27680     Document Type: Article

References (53)

1. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013; 19:1044-53; PMID:23460535; http://dx.doi.org/10.1158/1078-0432.CCR-12-2065.
2. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25:230-7; PMID:23414607; http://dx.doi. org/10.1016/j.coi.2013.01.004.
3. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11:1062-70; PMID:22532596; http://dx.doi.org/10.1158/1535-7163.MCT-11-0677.
4. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009; 157:9-19; PMID:19659765; http://dx.doi. org/10.1111/j.1365-2249.2009.03912.x.
5. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j. seminoncol.2010.09.008.
6. Lin GH, Liu Y, Ambagala T, Kwon BS, Ohashi PS, Watts TH. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One 2010; 5:e11003; PMID:20543982; http://dx.doi. org/10.1371/journal.pone.0011003.
7. May KF Jr., Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002; 62:3459-65; PMID:12067989.
8. Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, Lynch DH. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002; 169:1792-800; PMID:12165501.
9. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229:192-215; PMID:19426223; http://dx.doi. org/10.1111/j.1600-065X.2009.00765.x.
10. Sabbagh L, Pulle G, Liu Y, Tsitsikov EN, Watts TH. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol 2008; 180:8093-101; PMID:18523273.
11. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169:4882-8; PMID:12391199.
12. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 2013; 210:743-55; PMID:23547098; http://dx.doi.org/10.1084/jem.20121190.
13. Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, Wherry EJ, Reiner SL. Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol 2010; 185:4988-92; PMID:20935204; http://dx.doi.org/10.4049/jimmunol.1002042.
14. Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, Shin H, Hunter CA, Wherry EJ, Lindsten T, Reiner SL. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008; 321:408-11; PMID:18635804; http://dx.doi.org/10.1126/science.1159806.
15. Intlekofer AM, Takemoto N, Kao C, Banerjee A, Schambach F, Northrop JK, Shen H, Wherry EJ, Reiner SL. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 2007; 204:2015-21; PMID:17698591; http://dx.doi.org/10.1084/jem.20070841.
16. Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ, Lauer GM, Reiner SL, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012; 338:1220-5; PMID:23197535; http://dx.doi.org/10.1126/science.1229620.
17. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54:777-85; PMID:3261634; http://dx.doi.org/10.1016/S0092-8674(88)91043-4.
18. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109:651-9; PMID:11877473; http://dx.doi. org/10.1172/JCI0214184.
19. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172:4821-5; PMID:15067059.
20. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002; 168:2720-8; PMID:11884438.
21. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27; PMID:8287475; http://dx.doi. org/10.1016/0092-8674(94)90169-4.
22. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001; 61:2031-7; PMID:11280763.
23. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; PMID:21559358; http://dx.doi.org/10.1371/journal. pone.0019499.
24. Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 2011; 187:3555-64; PMID:21880986; http://dx.doi.org/10.4049/jimmunol.1101244.
25. Henson SM, Akbar AN. KLRG1-more than a marker for T cell senescence. Age (Dordr) 2009; 31:285-91; PMID:19479342; http://dx.doi.org/10.1007/s11357-009-9100-9.
26. Tessmer MS, Fugere C, Stevenaert F, Naidenko OV, Chong HJ, Leclercq G, Brossay L. KLRG1 binds cadherins and preferentially associates with SHIP-1. Int Immunol 2007; 19:391-400; PMID:17307799; http://dx.doi.org/10.1093/intimm/dxm004.
27. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001; Chapter 20:Unit 20 1.
28. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9176498; http://dx.doi. org/10.1038/nm0697-682.
29. Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 2011; 244:197-217; PMID:22017440; http://dx.doi.org/10.1111/j.1600-065X.2011.01063.x.
30. Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008;222:277-86; PMID:18364008; http://dx.doi. org/10.1111/j.1600-065X.2008.00621.x.
31. Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, Chang AE. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004; 64:8411-9; PMID:15548712; http://dx.doi.org/10.1158/0008-5472.CAN-04-0590.
32. Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, Yokoyama WM, Kim TY, Kwon BS. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 2007; 67:8891-9; PMID:17875731; http://dx.doi. org/10.1158/0008-5472.CAN-07-1056.
33. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res 2007; 67:7875-84; PMID:17699794; http://dx.doi.org/10.1158/0008-5472.CAN-06-1744.
34. Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 2009; 8:469-78; PMID:19190115; http://dx.doi.org/10.1158/1535-7163.MCT-08-0993.
35. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396.
36. Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, Chen L, Chen SH. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92:931-6; PMID:10841829; http://dx.doi.org/10.1093/jnci/92.11.931.
37. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009; 114:3431-8; PMID:19641184; http://dx.doi.org/10.1182/blood-2009-05-223958.
38. Murillo O, Dubrot J, Palazón A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009; 39:2424-36; PMID:19662633; http://dx.doi.org/10.1002/eji.200838958.
39. Li Q, Iuchi T, Jure-Kunkel MN, Chang AE. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci 2007; 3:455-62; PMID:18071585; http://dx.doi.org/10.7150/ijbs.3.455.
40. Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X, Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 2010; 185:3174-83; PMID:20713880; http://dx.doi.org/10.4049/jimmunol.1000749.
41. Hegel JK, Knieke K, Kolar P, Reiner SL, Brunner-Weinzierl MC. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Eur J Immunol 2009; 39:883-93; PMID:19224637; http://dx.doi.org/10.1002/eji.200838770.
42. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291:1-13; PMID:23772560; http://dx.doi. org/10.1111/nyas.12180.
43. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID:23390376.
44. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214.
45. Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, Mittler RS, Ahmed R. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol 2011; 187:1634-42; PMID:21742975; http://dx.doi. org/10.4049/jimmunol.1100077.
46. Xiao H, Huang B, Yuan Y, Li D, Han LF, Liu Y, Gong W, Wu FH, Zhang GM, Feng ZH. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007; 13:1823-30; PMID:17325342; http://dx.doi.org/10.1158/1078-0432.CCR-06-2154.
47. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, Reiner SL, Weinmann AS, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 2011; 12:663-71; PMID:21623380; http://dx.doi. org/10.1038/ni.2046.
48. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190:4899-909; PMID:23536636; http://dx.doi.org/10.4049/jimmunol.1300271.
49. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013; 2:e23849; PMID:23734331; http://dx.doi.org/10.4161/onci.23849.
50. Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 2011; 344:269-78; PMID:21086108; http://dx.doi. org/10.1007/82_2010_114.
51. Speiser DE. A molecular profile of T-cell exhaustion in cancer. Oncoimmunology 2012; 1:369-71; PMID:22737618; http://dx.doi.org/10.4161/onci.18342.
52. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34:236-50; PMID:21389874; http://dx.doi. org/10.1097/CJI.0b013e318209e7ec.
53. Wang C, Wen T, Routy JP, Bernard NF, Sekaly RP, Watts TH. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulationdependent rescue of functionally impaired HIVspecific CD8 T cells. J Immunol 2007; 179:8252-63; PMID:18056369.